Association of missense substitution of A49T and V89L in the SRD5A2 gene with prostate cancer in Turkish patients

被引:1
作者
Neijmann, Sebnem Tekin [1 ]
Kural, Alev [1 ]
Tinay, Ilker [2 ]
Livaoglu, Ayten [3 ]
Cevlik, Tulay [4 ]
Turkeri, Levent [2 ]
机构
[1] Bakirkoy Dr Sadi Konuk Res & Training Hosp, Dept Biochem, TR-34147 Istanbul, Turkey
[2] Marmara Univ, Pendik Res & Training Hosp Istanbul, Dept Urol, Istanbul, Turkey
[3] Trabzon Kanuni Res & Training Hosp, Trabzon, Turkey
[4] Marmara Univ, Dept Biochem, Pendik Res & Training Hosp, Istanbul, Turkey
来源
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | 2017年 / 42卷 / 01期
关键词
5 alpha-Reductase gene; Polymorphism; Prostate cancer; SRD5A2; gene; Missense substitution; 5-ALPHA-REDUCTASE TYPE-II; PATHOLOGICAL CHARACTERISTICS; ANDROGEN PATHWAY; RISK; POLYMORPHISMS; INHIBITORS; MEN; AGGRESSIVENESS; EPIDEMIOLOGY; METAANALYSIS;
D O I
10.1515/tjb-2016-0164
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objective: To determine the association of missense substitution of alanine 49 threonine (A49T) and valine 89 leucine (V89L) in the steroid-5-alpha-reductase type II (SRD5A2) gene with prostate cancer in Turkish patients. Methods: Eighty patients with prostate cancer and 76 healthy control subjects were evaluated for A49T and V89L polymorphisms in the SRD5A2 gene mutations via real time fluorescence PCR and melting curve analysis. Results: Patients and controls were similar in terms of allele frequencies for polymorphic markers A49T and V89L in the SRD5A2 gene. Most patients had T2b (51.3%), N0 (96.3%) stage tumors with Gleason Score of >= 6 (82.7%) and surgical margin in 28.8%. While 81.3% had no seminal vesicle invasion, 36.3% had capsular invasion. Carrying the 49T allele was associated with higher likelihood of positive surgical margin status (27.5% in 49A vs. 75.0% in 49T, p = 0.038) and Gleason Scores of >= 7 (47.5% in 49A vs. 100.0% in 49T, p = 0.032) than 49A allele. Conclusion: Our findings revealed no significant difference between patient and control groups in terms of allele frequencies of polymorphic markers in the SRD5A2 gene. T allele was only shown in the patient group. Carrying the 49T allele was associated with higher tumor aggressiveness in A49T polymorphism.
引用
收藏
页码:37 / 43
页数:7
相关论文
共 28 条
[1]   The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer:: Current state of knowledge [J].
Andriole, G ;
Bostwick, D ;
Civantos, F ;
Epstein, J ;
Lucia, MS ;
McConnell, J ;
Roehrborn, CG .
JOURNAL OF UROLOGY, 2005, 174 (06) :2098-2104
[2]   Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer [J].
Chang, BL ;
Zheng, SL ;
Isaacs, SD ;
Turner, AR ;
Bleecker, ER ;
Walsh, PC ;
Meyers, DA ;
Isaacs, WB ;
Xu, JF .
PROSTATE, 2003, 56 (01) :37-44
[3]   Association of prostate cancer risk and aggressiveness to androgen pathway genes:: SRD5A2, CYP17, and the AR [J].
Cicek, MS ;
Conti, DV ;
Curran, A ;
Neville, PJ ;
Paris, PL ;
Casey, G ;
Witte, JS .
PROSTATE, 2004, 59 (01) :69-76
[4]   Epidemiology of prostate cancer [J].
Crawford, ED .
UROLOGY, 2003, 62 (6A) :3-12
[5]   Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk:: An explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors [J].
Cussenot, Oliuier ;
Azzouzi, Abdel-Rahmene ;
Nicolaiew, Nathalie ;
Mangin, Philippe ;
Cormier, Luc ;
Fournier, Georges ;
Valeri, Antoine ;
Cancel-Tassin, Geraldine .
EUROPEAN UROLOGY, 2007, 52 (04) :1082-1089
[6]   The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population [J].
Giwercman, YL ;
Abrahamsson, PA ;
Giwercman, A ;
Gadaleanu, V ;
Ahlgren, G .
EUROPEAN UROLOGY, 2005, 48 (04) :679-685
[7]   SRD5A1 and SRD5A2 are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists [J].
Gu, Xin ;
Na, Rong ;
Huang, Tao ;
Wang, Li ;
Tao, Sha ;
Tian, Lu ;
Chen, Zhuo ;
Jiao, Yang ;
Kang, Jian ;
Zheng, Siqun ;
Xu, Jianfeng ;
Sun, Jielin ;
Qi, Jun .
JOURNAL OF UROLOGY, 2013, 190 (02) :615-619
[8]   Is low serum free testosterone a marker for high grade prostate cancer? [J].
Hoffman, MA ;
DeWolf, WC ;
Morgentaler, A .
JOURNAL OF UROLOGY, 2000, 163 (03) :824-827
[9]   Prostate cancer epidemiology [J].
Hsing, AW ;
Chokkalingam, AP .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 :1388-1413
[10]  
Jaffe JM, 2000, CANCER RES, V60, P1626